Investors
Recent News
AXIM® Biotechnologies Receives Notice of U.S. Patent Allowance for Three Separate Patents Including Its Rapid Point of Care Neutralizing Antibody Test
Leading Diagnostic Healthcare Company Highlights Value Proposition of Expanding IP Portfolio Which Includes 13 Different Filings and Allowances SAN DIEGO--(BUSINESS WIRE)--AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an...
Partner News: Verséa Ophthalmics Commences Phase 1 Launch of Novel Tear-based Point-of-Care (T-POC) Quantitative Testing Platform
Verséa Ophthalmics Commences Phase 1 Launch of Novel Tear-based Point-of-Care (T-POC) Quantitative Testing Platform Business Wire TAMPA, Fla. -- July 25, 2023 Verséa™ Ophthalmics, LLC, a division of Verséa Health, Inc. committed to delivering novel, high-value...
AXIM® Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide
Leading Diagnostic Healthcare Company Also Announces Over 50 Initial Clinic Commitments for Its Full Diagnostic Assay Platform SAN DIEGO, TBD DATE, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an...
AXIM® Biotechnologies Appoints Kurt Phinney as Chief Operating Officer to Drive Scaling and Optimization of Manufacturing Unit
Leading Diagnostic Healthcare Company Selects Accomplished Operations Executive to Spearhead Growth of Diagnostic Assays Manufacturing SAN DIEGO, CA, May 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM”...
AXIM® Biotechnologies Commences Commercial Manufacturing of FDA-Cleared Proprietary Ocular Diagnostic Assays
Leading Diagnostic Healthcare Company Begins Manufacturing of Ocular Immunoglobulin (IgE), Lactoferrin Tests to Fulfill Orders From Commercialization Partner SAN DIEGO, CA, April 11, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- AXIM Biotechnologies, Inc. (OTCQB: AXIM)...
AXIM® Biotechnologies Files Provisional Patent on Novel Methodology for Use in Optical Diagnostic Assay Manufacturing
Leading Diagnostic Healthcare Company Announces Provisional Patent Filing on Proprietary Use of Materials for Ophthalmological Test Strip Manufacturing SAN DIEGO, TBD DATE, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or...
AXIM® Biotechnologies Files Patent on Fentanyl Neutralizing Antibody Test, Applies for DEA License to Work With Controlled Substance
Diagnostic Healthcare Solutions Company Developing New Test Designed to Measure Neutralizing Antibodies of Deadly Opioid Fentanyl SAN DIEGO, TBD DATE, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an...
AXIM Biotechnologies CEO Issues Letter to Shareholders
Summary: In 2022, AXIM® finalized optimization of its R&D and manufacturing infrastructure to be used in its diagnostic program AXIM will continue to generate revenue from its two FDA-cleared dry eye disease (DED) diagnostic tests through commercialization partner...
AXIM® Biotechnologies Develops Novel Dual IgE/MMP-9 Rapid Ophthalmological Diagnostic Test; Files Provisional Patent
SAN DIEGO, Dec. 13, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, announced today that it has filed a provision patent application with...
AXIM Biotechnologies Commercial Partner Verséa Ophthalmics Highlights Benefits of AXIM’s Eye Diagnostic Solutions
SAN DIEGO, Dec. 06, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, today announced that its ophthalmic diagnostic tear based solutions...
AXIM® Biotechnologies Receives Initial Order for Diagnostic Solutions as Exclusive Partner Verséa Ophthalmics Commences Initial Commercial Launch
SAN DIEGO, Oct. 04, 2022 (GLOBE NEWSWIRE) — AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, announced today that it has received an initial order of 19,000...
AXIM® Biotechnologies Point-of-Care Diagnostic Test Platform Sales Commence With Verséa Ophthalmics’ Commercial Launch at AAO 2022
Sales of Point-of-Care Diagnostic Tests for Ocular Surface Disease Commence at the American Academy of Ophthalmology Annual Meeting Through Exclusive Partnership SAN DIEGO, Sept. 29, 2022 (GLOBE NEWSWIRE) — AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,”...
AXIM® Biotechnologies Signs Exclusive Global Commercialization Agreement With Verséa™ Ophthalmics for Distribution and Sales of Novel Ophthalmic Diagnostics Solutions
SAN DIEGO, Sept. 19, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech” or “AXIM”), an international healthcare solutions company targeting ocular surface diseases, announced today that it has signed an exclusive global commercial...
AXIM Biotechnologies Celebrates Feature on the Vision is More Than 20/20™ Podcast
SAN DIEGO, July 21, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface diseases, announced today that its CEO John Huemoeller has been...
AXIM Biotechnologies Publishes Study Highlighting Neutralizing Antibody Levels of Poor Vaccine Responders with a Third COVID-19 Vaccine Dose
SAN DIEGO, July 12, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company, announced today their publication in collaboration with researchers at Arizona State...
AXIM Launches New Eye Care Website; Establishes Platform for Commercialization
AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface diseases, today announced the launch of its new mobile-optimized website designed to provide doctors, researchers...
AXIM Biotechnologies Completes Optimization of Only FDA-Cleared IgE Rapid Diagnostics Test – In-House Manufacturing Lowers Cost and Eliminates Supply Chain Expenditures
SAN DIEGO, May 24, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface diseases announced today that its scientific team has completed the...
AXIM Biotechnologies Develops Novel Tear Sample Collector System, Files Patent Application
SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting dry eye disease (DED), today announced that it has developed a novel tear sample...
AXIM Develops Quantitative Rapid Diagnostic Test for Lacritin; Now Boasts Four Dry Eye Disease Point-of-Care Biomarker Tests
SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting Dry Eye Disease (DED), announced today that it has successfully developed a...
AXIM Biotechnologies CEO Issues Letter to Shareholders
Summary: AXIM places strategic focus on commercializing FDA-cleared Dry Eye Disease (DED) diagnostic system Plans to address largely underserved DED diagnosis market with patent pending tear collection method and approved tests, supported by world-class DED...
AXIM Biotech Develops Rapid Quantitative Tear Test for MMP-9, An Inflammatory Biomarker of Dry Eye Disease
SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting dry eye disease (DED), today announced that it has successfully developed a rapid...
AXIM Biotech Launches For Research Use Only Sales for its COVID-19 Neutralizing Antibody Test
SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting dry eye disease (DED), today announced that is has shifted its focus for its rapid...
AXIM Biotech Announces New Milestones in Preparation of Dry Eye Disease Diagnostics Launch
AXIM is driven to positively transform the state of Dry Eye Disease (DED) testing and diagnosis The company will deploy industry leader IUL’s state-of-the-art iPeak readers Company Adds Veteran Lab Testing Exec Barry Craig AXIM develops and files for a patent for...
CDC Publishes AXIM® Biotechnologies-Sponsored Study on COVID-19 Neutralizing Antibodies
SAN DIEGO, Dec. 21, 2021 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting COVID-19 diagnostics, oncological research, and dry eye disease, announced today...
AXIM Biotechnologies Applauds FDA’s Recent COVID-19 Test Policies to Support Rapid Neutralizing Antibody Tests
SAN DIEGO, Nov. 18, 2021 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” or “the Company”), an international healthcare solutions company targeting oncological, COVID-19 and Dry Eye Disease (DED) diagnostics, today applauds the FDA on...
AXIM Biotechnologies Partners with Arizona State University to Determine Antibody Levels Against COVID-19
SAN DIEGO, Nov. 16, 2021 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting COVID-19 diagnostics and oncological research, announced today that it has partnered...
AXIM Biotechnologies’ Development of Rapid Test for COVID-19 Neutralizing Antibodies is Cited to Demonstrate over 90% Sensitivity and 100% Specificity
Publication in the Journal of Clinical Virology Highlights Effectiveness of the Rapid Test To Identifying Immunity Levels of Functional Antibodies, Preventing the Virus from Infecting Cells SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB:...
AXIM Biotechnologies Appoints Clinical Research and DED Expert Dr. Michael E. Stern to its Medical Advisory Board
SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” or “the Company”), an international healthcare solutions company targeting oncological, COVID-19 and Dry Eye Disease (DED) diagnostics, today announced it has...
AXIM Biotechnologies Appoints Dry Eye Disease Expert and Accomplished Optometrist Dr. Kelly K. Nichols to its Medical Advisory Board
SAN DIEGO, Oct. 20, 2021 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” or “the Company”), an international healthcare solutions company targeting oncological, COVID-19 and dry eye disease (DED) diagnostics, today announced it has...
AXIM® Biotechnologies Develops Next Generation of its Rapid Neutralizing Antibody Test for COVID-19
SAN DIEGO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological, COVID-19 and dry eye disease (DED) diagnostics, today announced the...
AXIM® Biotechnologies Appoints Leading US Ophthalmic Surgeon and Researcher Dr. Henry D. Perry to its Medical Advisory Board
Dr. Perry is Third World-Class Ophthalmologist to Join the Advisory Board SAN DIEGO, Oct. 11, 2021 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” or “the Company”), an international healthcare solutions company targeting oncological,...
AXIM® Biotechnologies Appoints Senior DED Expert Dr. Laura Periman to its Medical Advisory Board
Dr. Periman Joins Chairman Joseph Tauber as Advisory Board’s Second Member SAN DIEGO, Oct. 05, 2021 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” or “the Company”), an international healthcare solutions company targeting oncological,...
AXIM® Biotechnologies Appoints Joseph Tauber, MD, Chief Medical Officer and Chairman of its Medical Advisory Board
SAN DIEGO, Sept. 21, 2021 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” or “the Company”), an international healthcare solutions company targeting oncological, COVID-19 and dry eye disease (DED) diagnostics, today announced that it has...
AXIM® Biotech Appoints Ophthalmic Industry Veteran Jeff Busby as Senior VP Business Development
Busby to Direct Dry Eye Disease Commercial Launch for Recently Acquired Diagnostic Tech SAN DIEGO -- September 15, 2021 -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a leader in the development of diagnostic testing for...
AXIM® Biotechnologies’ Manufacturing Partner Empowered Diagnostics Files Amended Emergency Use Authorization with FDA for its Rapid COVID-19 Neutralizing Antibody Test in Whole Blood at Point-of-Care Locations
SAN DIEGO, Aug. 30, 2021 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological, COVID-19 and dry eye disease diagnostics, announced today that the...
AXIM® Biotechnologies to Acquire Technology Including Two FDA-Cleared 510(k)’s for Diagnostic Testing of Dry Eye Disease
SAN DIEGO, Aug. 03, 2021 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a leader in the development of diagnostic testing for COVID-19 and cancer, announced today that the Company has signed a Binding Term...
AXIM® Biotechnologies Completes Pre-Clinical Drug Studies on SPX-1009 Compound Proving Suppression of Melanoma Cells
SAN DIEGO, May 26, 2021 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today that it has completed...
AXIM® Biotechnologies’ Manufacturing Partner Empowered Diagnostics Files for Approval for Use of Rapid COVID-19 Neutralizing Antibody Test in Whole Blood at Point-of-Care Locations in Canada and the EU
SAN DIEGO, May 05, 2021 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today that the Company’s...
AXIM Biotechnologies Introduces Diagnostics to Measure Immunity Against Emerging SARS-CoV-2 Variants
SAN DIEGO, May 03, 2021 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today a new ELISA test that measures...
AXIM® Biotechnologies’ Manufacturing Partner Empowered Diagnostics Files Emergency Use Authorization With FDA for Use of Its Rapid COVID-19 Neutralizing Antibody Test in Whole Blood at Point-of-Care Locations
SAN DIEGO – March 24, 2021 – AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today that the Company’s manufacturing partner,...
AXIM® Biotechnologies Successfully Completes Point-of-Care Clinical Trials on its Rapid COVID-19 Neutralizing Antibody Test
SAN DIEGO, March 08, 2021 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today that it has successfully...
AXIM® Biotechnologies Begins Clinical Trials of its ImmunoPass Rapid Diagnostic Test with Vaccine Recipients
SAN DIEGO – February 3, 2021 – AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announces initiation of clinical trials for ImmunoPass, the...
AXIM® Biotechnologies Releases Preprint Manuscript Describing the Development of Company’s Rapid Point-of-Care Test That Measures COVID-19 Neutralizing Antibodies
SAN DIEGO, January 11, 2021 -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today that it has released a preprint of its...
AXIM® Biotechnologies Completes Successful Covid-19 Live Virus Test and Files Amended EUA for Portable 10 Minute Rapid Diagnostic Test for Neutralizing Antibodies
SAN DIEGO – December 15, 2020 – AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today that it has filed an amended Emergency Use...
AXIM® Biotechnologies to Present at the 13th Annual LD Micro Main Event Investor Conference on Monday, December 14
SAN DIEGO – December 14, 2020 – AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today that the Company’s CEO John W. Huemoeller...
AXIM® Biotechnologies Develops ELISA-Based Neutralizing Antibody Diagnostic Test for COVID-19 and Applies for Patent; Company’s Fourth COVID-19 Test-Focused Patent Application
SAN DIEGO, December 3, 2020 -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or the “Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today the development and patent filing for an...
AXIM® Biotechnologies Applauds Vaccine Producers, Highlights Need for Rapid Antibody Testing to Ensure Immunity
SAN DIEGO, Nov. 10, 2020 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, applauds the recent announcement from a major...
AXIM® Biotechnologies Issues Update Letter to Shareholders
SAN DIEGO, October 28, 2020 — AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today that it has issued a letter to its...
AXIM® Biotechnologies Files Patent for Virus Binding Recombinant Protein for SARS-CoV-2 (COVID-19) and Begins Manufacturing
SAN DIEGO, September 30, 2020 -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today that it has filed a provisional patent for...
AXIM® Biotechnologies Files Patent for World’s First Face Mask Designed to Capture SARS-CoV-2 COVID-19
SAN DIEGO, September 29, 2020 -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today that it has filed a provisional patent for...
AXIM® Biotechnologies Receives Notice of U.S. Patent Allowance for Proprietary Compounds and Methods Targeting Tumor Metastasis Through QSOX1
SAN DIEGO – September 22, 2020 – AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today that the United States Patent and...
AXIM® Biotechnologies Files Emergency Use Authorization With the FDA for First–in-Class COVID-19 Rapid Diagnostic Test for Neutralizing Antibodies
SAN DIEGO – September 16, 2020 – AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today it has filed an Emergency Use...
AXIM® Biotechnologies Signs Exclusive Licensing, Manufacturing and Distribution Agreement for High Volume Production of the COVID-19 Rapid Neutralizing Antibody Test
SAN DIEGO, August 24, 2020 -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today that the Company has signed an exclusive...
Sapphire Biotech, Subsidiary of AXIM® Biotechnologies, Awarded Prestigious Phase I Small Business Innovation Research Grant by National Cancer Institute
SAN DIEGO – August 11, 2020 – AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announces that its wholly-owned research and development...
AXIM® Biotechnologies Applies for FDA Emergency Use Approval (EUA) for High Throughput, Patent-Pending Neutralizing Antibody Diagnostic Test for COVID-19
SAN DIEGO, August 5, 2020 -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today the development, patent filing and Emergency...
AXIM® Biotechnologies Releases Rapid NeuCovix™ Test Results Showing Strong Agreement with COVID-19-Based Neutralization Tests
AXIM® Biotechnologies Releases Rapid NeuCovix™ Test Results Showing Strong Agreement with COVID-19-Based Neutralization Tests SAN DIEGO – July 23, 2020 – AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare...
AXIM® Biotechnologies Welcomes Former Secretary of Veterans Affairs Peter O’Rourke to Company’s Board of Directors
SAN DIEGO, July 21, 2020 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) ("AXIM® Biotech," "AXIM" or "the Company"), an international healthcare solutions company targeting oncological and COVID-19 research, announced today it has welcomed Former...
AXIM® Biotechnologies Unveils First–in-Class COVID-19 Rapid Diagnostic Test for Neutralizing Antibodies and Files Pre-Emergency Use Authorization with the FDA
SAN DIEGO, July 15, 2020 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological research, today announced the development of NeuCovixTM, a rapid...
AXIM® Biotechnologies Appoints Dr. Alim Seit-Nebi as Chief Technology Officer of Subsidiary Sapphire Biotech
SAN DIEGO – June 9, 2020 – AXIM® Biotechnologies, Inc. (OTCQB: AXIM) ("AXIM® Biotech," "AXIM" or "the Company"), an international healthcare solutions company targeting oncological research, announced today it has appointed Dr. Alim Seit-Nebi as the Chief Technology...
AXIM® Biotechnologies Begins Pre-Clinical Pharmacokinetic Animal Drug Studies on its Cancer Drug Compound SPX-1009
SAN DIEGO, June 1, 2020 -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological research, announced today that its subsidiary Sapphire Biotech, Inc. (“Sapphire”) has...
AXIM® Biotechnologies Expands Research Division and Announces Dr. Sergei Svarovsky as Chief Scientific Officer of Subsidiary Sapphire Biotech
SAN DIEGO – May 27, 2020 – AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and cannabinoid research, announced today it has expanded its research division through...
AXIM® Biotechnologies Files for Patent for Unique Biomarker for Early Detection of Cancer in Blood
AXIM® Biotechnologies Files for Patent for Unique Biomarker for Early Detection of Cancer in Blood NEW YORK – May 18, 2020 – AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting...
AXIM® Biotechnologies Issues Update Letter to Shareholders
SAN DIEGO, May 13, 2020 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and cannabinoid research, announced today that it has issued a letter...
AXIM® Biotechnologies Files New U.S. Patent Application for Water-Soluble Cannabinoid Molecules
NEW YORK, April 28, 2020 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTC: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and cannabinoid research, announced today that the Company has filed an...
AXIM® Biotechnologies Completes Pre-Clinical Drug Studies on New Compound Proving Tenfold Greater Inhibition of Tumor Metastasis Than Parent Compound
SAN DIEGO, March 24, 2020 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and cannabinoid research, announced today that its...
AXIM® Biotechnologies Completes Acquisition of Oncology Research and Development Company Sapphire Biotech, Inc.
NEW YORK, March 18, 2020 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and cannabinoid research, announced today that the Company has...
AXIM® Biotechnologies Acquiree Sapphire Biotech, Inc. Signs License Agreement to Exclusively License Patent Rights in Cancer Technology
SAN DIEGO, Jan. 22, 2020 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological research, announced today that its acquiree Sapphire Biotech, Inc....
AXIM® Biotechnologies to Acquire Leading Oncology Research and Development Company Sapphire Biotech, Inc.
AXIM® Biotechnologies to Acquire Leading Oncology Research and Development Company Sapphire Biotech, Inc. January 08, 2020 SAN DIEGO, Jan. 08, 2020 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a world leader...
AXIM® Biotechnologies Announces Cultivation Agreement to Establish Company’s First Domestic Industrial Hemp Source & Begins Harvesting
AN DIEGO, Sept. 17, 2019 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (“AXIM® Biotech,” “AXIM” or “the Company”) (OTCQB: AXIM), a world leader in cannabinoid research and development, today announced that it has signed a cultivation agreement with a top hemp farm...
AXIM® Biotechnologies, Inc. Signs Cannabinoid Product Supply Agreement with Healthcare Company for Clinical Trials on Treatment of Periodontitis
NEW YORK, June 03, 2019 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTC: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a world leader in cannabinoid research and product development, today announced that it has signed a cannabinoid product supply agreement...
Email Alerts
Stay informed and receive company updates straight to your inbox
